top of page

 BioMimetic Cap System & BioCore Tooth Injection System

Build the Root. Then the Smile.

Patent Pending

​​DTC proposes a two-stage dental technology platform designed to reduce the lifetime escalation cycle of restorative dentistry: repeated fillings, cusp fracture, crowns, root canals, extractions, and implants.

 

The platform is built around two linked product families:

Stage 1: BioMimetic Cap System
A near-term tooth-preservation system using adhesive tooth-shell restoration, precision injection, occlusal forming matrices, and conservative cuspal coverage to restore compromised teeth before structural failure.

​

Stage 2: BioCore Tooth Injection System
A longer-term nonmetal root-formation and tooth-replacement platform using guided acrylic mouthpieces, dual-tube injection/vent pathways, BioCore adhesive structural material, and digitally planned root-form implant foundations.

​

DTC’s leadership position traces back to the 2000 era, when the concept direction was first being researched through dental guide and prosthetic placement modeling, including a one-time-use prosthetic drill guide solid model for Wickert Dental Lab.

 

That early work anticipated a larger industry shift: dentistry would eventually move from reactive repair and metallic anchoring toward guided placement, biomimetic bonding, digital matrices, and lifecycle tooth preservation.

​

The commercial strategy is to launch first with the lower-risk BioMimetic Cap System, then use clinical, material, and market traction to fund the deeper development path for BioCore Tooth Injection System.

​

The opportunity is substantial. The dental implant market alone is estimated in the low-to-mid billions globally, with multiple 2025 estimates placing it around $5.1 billion to $5.6 billion and projecting growth toward roughly $8 billion to $11 billion by the early 2030s. ([Grand View Research][1]) The broader addressable market includes fillings, crowns, onlays, endodontics, dental lab workflows, guided surgery, bone grafting materials, implant components, and restorative materials.

​

Mission

To establish a new leadership category in dentistry: biomimetic lifecycle restoration, preserving teeth earlier and replacing them more biologically when preservation is no longer possible.

​

Core Thesis

Traditional dentistry often waits until structural failure becomes obvious. DTC’s approach is to intervene earlier and more intelligently.

​

Current escalation model:
Small filling → larger filling → cusp fatigue → fracture → crown → root canal risk → extraction → implant.

​

DTC lifecycle model:
Structural risk detection → adhesive biomimetic cap → tooth-shell reinforcement → reduced fracture escalation → nonmetal BioCore replacement only when natural tooth preservation is no longer practical.

​

Product Stage 1: BioMimetic Cap System

Product Definition

BioMimetic Cap System is a tooth-preserving adhesive cap platform designed for structural restoration, cusp protection, and lifecycle dental cost reduction.

​

The system combines:

  • Precision restorative injection

  • Clear occlusal forming matrices

  • Adhesive bonding protocols

  • Cuspal-coverage preparation guides

  • Layered dentin/enamel restorative material strategy

  • Polishing and surface-sealing workflow

  • Digital matrix design option

  • Clinical documentation and risk scoring

​

Target Applications

  • Large failing fillings

  • Old amalgam replacement

  • Cracked cusp prevention

  • Sharp biting pain from structural fatigue

  • Posterior molars and premolars

  • Endodontic access restoration

  • Pre-crown stabilization

  • Patients seeking conservative alternatives to full crowns

  • Early-stage filling-fracture-crown escalation case

 

​

Product Components

​BioCap Precision Injector
A controlled hand or pneumatic delivery tool for restorative material placement.

​

BioCap MicroTips
Disposable sterile micro-nozzles for precise material placement.

​

BioCap Flow Cartridges
Compatible injectable restorative materials, initially using validated existing composite families

before proprietary materials mature.

 

BioCap Form Matrices
Clear occlusal forming matrices that help shape the chewing anatomy and reduce freehand variability.

 

BioCap CoreFiber
A structural reinforcement layer for stress distribution in large restorations.

 

BioCap EnamelShell
Final polishable, wear-resistant occlusal layer.

 

BioCap FinishSeal
Final finishing, polishing, and surface-sealing kit.

 

BioCap DigitalForm
Scan-to-matrix dental lab workflow for custom occlusal forms.

 Near-Term Development Strategy

 

The first commercial stage should avoid high-risk implant claims. It should enter through restorative workflow, education, non-implant chairside tools, and dental lab support.

​

Initial products can include:

  • Training protocol

  • Matrix design workflow

  • Procedure kits

  • Injection tips

  • Occlusal forms

  • Documentation templates

  • Case-selection system

  • Clinical education package

​

The restorative material can initially rely on existing cleared dental composites and bonding systems while DTC develops proprietary delivery, matrix, and workflow IP.

​

Regulatory Strategy

The BioMimetic Cap System should be staged carefully. General dental restorative composites are regulated dental devices, and FDA has guidance for dental composite resin 510(k) submissions. For the first launch, DTC should prioritize accessory tools, matrices, and workflow components that can pair with existing approved materials, then pursue device-specific regulatory pathways as proprietary materials and injectors mature.

​

 Stage 1 Development Budget

  • Concept refinement, engineering design, and IP drafting: $150,000–$350,000

  • Prototype injector, tips, matrices, and lab workflow: $250,000–$750,000

  • Dental advisory board and clinical protocol development: $100,000–$250,000

  • Benchtop testing and materials compatibility: $250,000–$600,000

  • Pilot dentist case documentation program: $300,000–$900,000

  • Regulatory consulting and quality system setup: $250,000–$750,000

  • Initial tooling for disposable tips/matrices: $500,000–$1.5 million

  • Branding, publication ads, website, investor deck, KOL outreach: $150,000–$500,000

  • Initial working capital: $500,000–$1.5 million

​

Estimated Stage 1 total: $2.4 million–$7.1 million

 

Stage 1 Revenue Model

Revenue can come from:

  • Disposable procedure kits

  • Injector sales or leasing

  • Matrix kits

  • DigitalForm lab service

  • Training certification

  • Clinical documentation software

  • Dental lab partnerships

  • Material cartridge licensing

  • Distributor partnerships

​

Stage 1 Target Pricing

  • BioCap starter system: $2,500–$7,500 per dental office

  • Procedure kit: $65–$175 per case

  • Custom digital matrix: $75–$250 per case

  • Training certification: $750–$2,500 per clinician

  • Premium injector: $5,000–$18,000 depending on manual, pneumatic, or smart version

​

Stage 1 ROI Logic

A conservative early market model:

  • 500 dentists using 8 cases/month at $95 disposable revenue per case:

  • 500 × 8 × 12 × $95 = $4.56 million annual consumable revenue

  • 2,500 dentists using 10 cases/month at $95 per case:

  • 2,500 × 10 × 12 × $95 = $28.5 million annual consumable revenue

  • 10,000 dentists using 10 cases/month at $95 per case:

  • 10,000 × 10 × 12 × $95 = $114 million annual consumable revenue

​

This excludes injector sales, digital matrices, training, premium material licensing, and dental lab revenue.

​

If gross margins on consumables reach 60%–75%, Stage 1 can become a cash-generating platform to fund Stage 2.

​

Product Stage 2: BioCore Tooth Injection System

  • Product Definition

  • BioCore Tooth Injection System is a guided, nonmetal, biomimetic root-formation platform designed to create a structural implant foundation through controlled injection, dual-tube flow/vent management, acrylic mouthpiece guidance, and restorative integration.

 

The concept uses:

  • Full-arch acrylic placement guide

  • Bite-down stabilization geometry

  • Root-form implant chamber

  • Dual-tube injection and vent pathways

  • BioCore structural adhesive material

  • Pressure-limited delivery syringe

  • Digital planning and guided osteotomy

  • Radiopaque material tracking

  • Restorative build-up interface

  • Final BioMimetic tooth/crown restoration

  •  Technology Concept

 

Instead of placing a conventional metallic screw implant, the system prepares a guided osteotomy or socket and forms a BioCore root foundation using a controlled injection process.

 

The intended workflow:

  • Digital scan and CBCT planning

  • Custom full-arch acrylic guide design

  • Guided osteotomy or socket preparation

  • Acrylic guide placed in the mouth with bite-down stabilization

  • Dual-tube pathway connected to adhesive syringe

  • BioCore material injected into root-form chamber

  • Vent path removes displaced fluid/air

  • BioCore sets into a structural root foundation

  • Healing and integration period

  • Final tooth restoration bonded or injected onto BioCore foundation

 

Technical Differentiation

BioCore should not be positioned as “glue.” It should be positioned as a structural, bioactive implant-core material.

​

Differentiators:

  • Nonmetal direction

  • Guided injection rather than threaded implant insertion

  • Root-form geometry

  • Full-arch stabilization

  • In-flow and vent pathway

  • Potential reduced hardware inventory

  • Future regenerative chemistry pathway

  • Material continuity from root foundation to crown restoration

  • Digital planning and custom acrylic guide workflow

 

Key Technical Challenges

  • Wet-field bonding in blood and bone fluid

  • Setting behavior inside a confined osteotomy

  • Radiographic visibility

  • BioCore fatigue strength under chewing loads

  • Bone-interface integration

  • Thermal safety during setting

  • Bacterial leakage prevention

  • Soft-tissue seal at gumline

  • Retrievability or revision strategy

  • Long-term load transfer

  • Regulatory burden

  • Animal and human clinical evidence

  •  Adhesive and Material Development

 

The BioCore material cannot be ordinary dental composite.

 

It requires a specialized formulation with:

  • Calcium phosphate or hydroxyapatite phase

  • Bioactive ceramic reinforcement

  • Radiopaque filler

  • Wet-field compatible chemistry

  • Controlled viscosity for injection

  • Dual-cure or self-setting behavior

  • Low exotherm

  • High compressive strength

  • Fatigue resistance

  • Micro-porous or bone-integrating interface

  • Dense structural core

  • Potential remodeling or osteoconductive outer phase

  • Sterile cartridge packaging

 

A useful technology direction is a two-zone system:

  • BioCore Inner Structure: dense, fatigue-resistant, structural core.

  • BioCore OsteoInterface: bioactive, bone-compatible outer interface designed for osseointegration or bone bonding.

 

FDA’s 2025 guidance on animal studies for dental bone grafting material devices is relevant because dental bone grafting materials are intended to fill, augment, or reconstruct periodontal or bony defects of the oral and maxillofacial region, and the guidance provides recommendations for animal studies supporting 510(k) submissions. 

​

Equipment Development

BioCore Precision Syringe

  • A controlled delivery syringe or pneumatic injector.

  • Dual-Tube Delivery Set

  • One tube for material inflow and one for venting/fluid displacement.

  • BioCore GuidePort

  • A guide-integrated inlet/vent port system.

  • Full-Arch Acrylic Guide

  • Bite-stabilized mouthpiece with root-form chamber.

  • Pressure-Limiting Module

  • Prevents overpressure and unintended material extrusion.

  • Radiographic Verification Workflow

  • Material and guide markers visible under imaging.

​

Smart Injector Option
Flow sensing, pressure sensing, material recognition, and procedure logging.

Tooling and Manufacturing Requirements

​

Stage 1 tooling:

  • Injection molded disposable tips

  • Clear matrix molds

  • Cartridge components

  • Basic injector components

  • Packaging trays

  • Sterilizable or disposable components

 

Stage 2 tooling:

  • Custom acrylic guide manufacturing

  • High-precision tubing assemblies

  • Medical-grade syringe assemblies

  • Sterile cartridge filling line

  • Root-form guide sleeves

  • Radiopaque marker integration

  • Pneumatic or smart injector assembly

  • Cleanroom-compatible packaging

  • Biomaterial mixing and filling equipment

 

Equipment Investment Estimate

  • Prototype dental lab equipment: $150,000–$500,000

  • Includes scanners, printers, curing units, finishing tools, guide fabrication capability.

  • Benchtop material lab: $500,000–$1.5 million

  • Includes mixers, rheometers, mechanical testing, curing analysis, environmental aging, microscopy access.

  • Pilot clean assembly area: $750,000–$2.5 million

  • For sterile or controlled assembly of tubing, tips, syringes, cartridges, and guide kits.

  • Pilot cartridge filling equipment: $1 million–$4 million

  • Depending on whether outsourced or in-house.

  • Quality system and validation infrastructure: $500,000–$2 million

  • Design controls, traceability, supplier qualification, process validation, sterilization validation.

  • Preclinical testing equipment and outsourced lab work: $1 million–$4 million

  • Estimated Stage 2 equipment and infrastructure: $3.9 million–$14.5 million before major clinical trials.

 

Clinical Development Plan

Stage 1 Clinical Program: BioMimetic Cap System

 

Goal: Establish safety, usability, survival rate, reduced fracture progression, patient satisfaction, and procedure economics.

​

Phase A: Bench and simulated-use testing

  • Bond strength

  • Marginal integrity

  • Wear testing

  • Thermal cycling

  • Fatigue testing

  • Matrix accuracy

  • Curing depth

  • Material compatibility

 

Phase B: Dentist usability program

  • 10–25 dentists

  • 50–150 cases

  • Workflow timing

  • Matrix fit

  • Restoration quality

  • Failure modes

  • Training requirements

​

Phase C: Observational clinical registry

  • 25–100 dentists

  • 500–2,000 cases

  • 12–36 month follow-up

  • Fracture rate

  • Retreatment rate

  • Sensitivity

  • Patient satisfaction

  • Crown avoidance tracking

​

Phase D: Comparative clinical study

  • BioMimetic Cap vs conventional large filling/onlay/crown pathway.

  • Endpoints: survival, fracture prevention, cost, patient comfort, time to retreatment.

  • Estimated Stage 1 clinical cost: $1 million–$5 million depending on study design.

 

Stage 2 Clinical Program: BioCore Tooth Injection System

Goal: Prove that BioCore can safely form a structural root foundation, integrate with bone, support restorative build-up, and compete with selected implant indications.

 

Phase A: Benchtop feasibility

  • Material setting kinetics

  • Wet-field bonding

  • Compression

  • Flexural strength

  • Pullout strength

  • Fatigue

  • Microleakage

  • Radiopacity

  • Sterility and shelf life

 

Phase B: Cadaver/synthetic jaw testing

  • Guide fit

  • Osteotomy alignment

  • Injection fill completeness

  • Vent effectiveness

  • Pressure profile

  • Removal/revision strategy

  • Phase C: Animal study

  • Bone response

  • Histology

  • MicroCT

  • Inflammation

  • Bone-to-material contact

  • Integration over time

  • Mechanical stability

  • Infection risk

 

Phase D: First-in-human feasibility

  • Highly selected cases

  • Single-tooth sites

  • Delayed loading

  • Careful imaging follow-up

  • Safety endpoints

 

Phase E: Pivotal trial
BioCore vs conventional implant or socket-preservation/control pathway.
 

Endpoints: survival, stability, integration, bone levels, peri-implant tissue health, restorative success, patient-reported outcomes.

​

Estimated Stage 2 clinical/preclinical cost: $8 million–$35 million before broad commercialization.

​

Regulatory Strategy

Stage 1

Focus on restorative accessories, guide/matrix workflow, and compatibility with existing cleared materials first. Proprietary restorative materials and injectors can follow.

Likely regulatory areas:

  • Dental restorative material

  • Dental injector/accessory

  • Matrix/forming guide

  • Dental lab workflow

  • 510(k) strategy depending on claims and predicates

 

Stage 2

This is a higher regulatory burden product because it involves an implanted structural material with prolonged bone contact.

​

Likely regulatory areas:

  • Endosseous implant concepts

  • Dental bone grafting/bone void filling material

  • Sterile delivery system

  • Dental surgical guide

  • Biocompatibility testing

  • Animal studies

 

Clinical trial requirements

FDA identifies dental bone grafting material devices as Class II devices and has special controls guidance for this category.

​

Root-form dental implants and abutments also fall under specific FDA dental device categories, requiring a more rigorous device-development and biocompatibility strategy.

 

Intellectual Property Strategy

Core Patent Families

Patent Family 1: BioMimetic Cap Method
Adhesive tooth-shell restoration method for compromised posterior teeth.

​

Patent Family 2: Occlusal Matrix System
Clear forming matrix for cuspal-coverage injection restoration.

​

Patent Family 3: Precision Dental Injector
Pressure-limited, material-specific restorative delivery device.

​

Patent Family 4: DigitalForm Workflow
Scan-to-matrix design and lab-manufacturing workflow.

​

Patent Family 5: BioCore Root-Form Injection Guide
Full-arch acrylic mouthpiece with bite stabilization and root-form chamber.

​

Patent Family 6: Dual-Tube Root Injection System
Inlet and vent tubing pathway for controlled root-form material placement.

​

Patent Family 7: BioCore Material System
Structural bioactive injectable implant-core material.

​

Patent Family 8: BioCore Restoration Interface
Bonding architecture between injected root foundation and final tooth/crown restoration.

​

Manufacturing Plan

Stage 1 Manufacturing

Outsource initially to reduce capital risk.

​

Partners needed:

  • Dental injection molding supplier

  • Medical/dental disposable packaging supplier

  • Dental lab partner

  • 3D printing/CAD dental lab partner

  • Sterilization partner if required

  • Composite material partner

  • Quality/regulatory consultant

 

Stage 2 Manufacturing

Hybrid in-house and outsourced model.

 

Build internally:

  • Design controls

  • Guide design software workflow

  • Critical material formulation knowledge

  • Quality management

  • Clinical data program

  • IP and know-how

​

Outsource or partner:

  • Sterile filling

  • Tubing assemblies

  • Syringe components

  • Acrylic guide fabrication at scale

  • Material testing

  • Animal studies

  • Clinical trial operations

​

Commercial Strategy

Beachhead Market

Biomimetic dentists, advanced restorative dentists, prosthodontists, high-end general dentists, and dental labs already using digital dentistry.

​

Adoption Strategy

Launch through education and case documentation, not generic commodity distribution.

​

Channels:

  • KOL dentists

  • Dental continuing education

  • Dental publication ads

  • Before/after case libraries

  • Dental lab partnerships

  • YouTube/clinical technique demonstrations

  • Dental schools and residency programs

  • Biomimetic dentistry associations

  • Trade shows

  • Premium practice groups

  • DSO pilot programs

 

Sales Model

Stage 1:

  • Direct-to-dentist starter kits

  • Distributor partnerships

  • Lab-based custom matrix service

  • Training and certification

  • Recurring consumable sales

​

Stage 2:

Specialist channel

  • Oral surgeons

  • Periodontists

  • Prosthodontists

  • Implant centers

  • Regenerative dentistry partners


Strategic acquisition or licensing to major dental implant company

​

Financial Model

Stage 1 Five-Year Projection

Year 1: R&D, prototype, advisory board, early pilots
Revenue: $0–$500,000
Expense: $2 million–$5 million

 

Year 2: limited launch, education, early kits
Revenue: $1 million–$4 million
Expense: $3 million–$7 million

 

Year 3: 500–1,500 dentist adoption
Revenue: $5 million–$18 million
Expense: $5 million–$10 million

 

Year 4: 2,500–5,000 dentist adoption
Revenue: $20 million–$60 million
Expense: $12 million–$25 million

 

Year 5: 7,500–12,000 dentist adoption
Revenue: $75 million–$150 million
Expense: $30 million–$60 million

 

Potential gross margin: 55%–75% on disposable kits and matrices.

 

Stage 2 Ten-Year Projection

Stage 2 has a longer timeline and higher risk.

  • Years 1–2: material feasibility, IP, bench testing

  • Years 3–4: preclinical studies and guide/injector development

  • Years 5–6: early human feasibility

  • Years 7–8: pivotal trial and regulatory submission

  • Years 9–10: limited commercial launch or strategic partnership

 

Potential per-case revenue:

  • BioCore guide: $250–$750

  • BioCore material cartridge: $300–$1,200

  • Tubing/syringe kit: $150–$500

  • Restorative interface kit: $200–$800


Total system revenue per case: $900–$3,250 before final restoration pricing.

​

If adopted in 25,000 cases/year at $1,500 average system revenue:

25,000 × $1,500 = $37.5 million annual revenue

​

If adopted in 100,000 cases/year:

100,000 × $1,500 = $150 million annual revenue

​

If adopted in 250,000 cases/year:

250,000 × $1,500 = $375 million annual revenue

​

The larger financial upside may come from acquisition or licensing by a major dental implant, regenerative materials, or digital dentistry company.

​

Investment Requirements

Seed Round: $1.5 million–$3 million

Use of funds:

  • IP filings

  • Product design

  • Initial prototypes

  • Dental advisory board

  • Market validation

  • Branding

 

Stage 1 business development
Material feasibility screening

Series A: $5 million–$10 million

 

Use of funds:

  • BioMimetic Cap System prototype refinement

  • Injection tools

  • Matrix tooling

  • Pilot manufacturing

  • Clinical registry

  • Quality system

  • Regulatory pathway

  • Initial commercial launch

 

Series B: $15 million–$35 million

Use of funds:

  • Scale Stage 1 commercialization

  • Develop BioCore material

  • Preclinical BioCore testing

  • Guide/tubing/syringe platform

  • Animal studies

  • Regulatory submissions


Strategic partnerships

Series C or Strategic Partner: $40 million–$100 million

 

Use of funds:

  • Human clinical trials

  • Manufacturing scale-up

  • Sterile filling line

  • International regulatory strategy

  • Implant-market commercialization

  • Major DSO/specialist channel launch

  •  Return on Investment

  •  Investor ROI Pathways

 

Path 1: Stage 1 cash-flow company
BioMimetic Cap System becomes a consumable-based restorative platform.

 

Path 2: Strategic acquisition
Dental materials, implant, or digital dentistry company acquires the platform after clinical adoption.

 

Path 3: Licensing model
License BioCap matrix/injector workflow and BioCore material/guide technology to established dental manufacturers.

 

Path 4: Dual-platform company
Use Stage 1 revenue to finance BioCore, creating a higher-value regenerative/restorative platform.

 

Potential Exit Logic

If Stage 1 reaches $50 million annual revenue with strong recurring consumables and 60%+ gross margin, a strategic acquirer could value it at 3×–8× revenue depending on growth, defensibility, and clinical evidence.

 

Potential Stage 1 valuation range at $50 million revenue:

$150 million–$400 million

 

If BioCore demonstrates credible preclinical or early clinical success, the platform value can increase substantially because it enters implant, regenerative material, and surgical guide markets.

 

Potential combined strategic value after strong Stage 2 validation:

$500 million–$1.5 billion+ depending on clinical performance, regulatory progress, and partner interest.

 

Risk Analysis

Technical Risks

  • BioCore wet-field bonding may not achieve sufficient stability.

  • Material may fail fatigue testing.

  • Injection fill may create voids.

  • BioCore may not integrate predictably with bone.

  • Heat generation or setting chemistry may create tissue risk.

  • Soft-tissue seal may be difficult.

 

Clinical Risks

  • Dentists may prefer existing crowns and implants.

  • Clinical trials may take longer than expected.

  • Patient selection may be narrow.

  • Long-term failure modes may appear late.

 

Regulatory Risks

  • BioCore may require higher regulatory burden than expected.

  • Combination-device concerns may arise if biologic or drug claims are made.

  • Animal and human studies may expand in cost.

​

Business Risks

  • Dental distribution can be slow.

  • KOL adoption is required.

  • Insurance reimbursement may lag.

  • Large competitors may develop adjacent systems.

 

Risk Reduction Strategy

  • Launch Stage 1 first.

  • Avoid implant claims until evidence supports them.

  • Use existing restorative materials initially.

  • Build clinical registry early.

  • Partner with biomimetic dentists and dental labs.

  • Patent workflow, guide, tubing, matrix, and material architecture.

  • Use outsourced manufacturing before heavy capital investment.

  • Pursue strategic dental-material partnerships.


Keep BioCore as a staged R&D platform until technical evidence is strong.

​

Milestone Roadmap

0–6 Months

  • Finalize product architecture

  • File provisional patents

  • Build advisory board

  • Create investor deck and publication ads

  • Prototype BioCap injector and matrices

  • Begin material compatibility testing

  • Identify dental lab partners

​

6–18 Months

  • Prototype BioMimetic Cap System

  • Pilot cases with selected dentists

  • Develop digital matrix workflow

  • Create clinical protocol

  • Begin quality system setup

  • Refine disposable kit economics

  • Start BioCore material feasibility work

 

18–36 Months

  • Launch limited BioCap system

  • Collect 500+ cases in registry

  • Tool first disposable components

  • Start BioCore bench testing

  • Build full-arch acrylic guide prototypes

  • Test dual-tube injection/vent system

  • Engage FDA/regulatory consultants

 

36–60 Months

  • Scale BioCap commercialization

  • Launch BioCap DigitalForm lab service

  • Begin BioCore preclinical testing

  • Develop BioCore material and syringe system

  • Perform synthetic jaw and cadaver workflow testing

  • Seek strategic partner discussions

 

5–10 Years

  • BioCore animal studies

  • First-in-human feasibility

  • Pivotal clinical pathway

  • Regulatory submissions

  • Implant-specialist launch or strategic acquisition

 

Strategic Conclusion

The strongest plan is a two-stage platform.

​

BioMimetic Cap System is the near-term commercial entry: conservative, biomimetic, lower regulatory risk, high-volume, and aligned with the existing restorative market.

 

BioCore Tooth Injection System is the long-term breakthrough platform: nonmetal, guided, injectable, root-form, regenerative, and potentially disruptive to conventional implant thinking.

 

DTC’s leadership story is powerful because the concept traces back to the 2000 era, when guided prosthetic placement and dental device modeling were already part of the research direction.

The industry is now finally converging toward the ideas DTC anticipated: digital guides, biomimetic

restoration, adhesive dentistry, minimally invasive preservation, injectable biomaterials, and non-metal implant alternatives.

 

The business should be presented as:

A staged dental technology platform that starts by preserving compromised teeth earlier, then advances toward guided non-metal root formation when tooth replacement is unavoidable.

​
 

image.png

© 2026 Design Team Collaboration, Est. 1997

bottom of page